Sales reps' presence tied to heart stent use
NEW YORK (Reuters Health) - Having sales representatives from medical device companies at hospitals may influence which products doctors use and ultimately drive up costs, according to a new study from Canada. Researchers found that doctors were more likely to use a company's drug-coated heart stent when one of its sales representatives visited their hospital, which resulted in about a $250 higher bill per case. "We need to evaluate carefully any interactions with medical industry to ensure that we minimize an effect on our decision making process," wrote Dr. Shahar Lavi, the study's lead author, in an email to Reuters Health.
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- EHR Systems 'Immature, Costly,' AMA Says
- Data Points to Boom in Private HIX
- Few Winners Among MSSP Participants
- Technology Lights Up Health Innovation Forum
- Interstate Medical Licensure Effort Advances
- How to Build a Health Plan from Scratch
- Better HCAHPS Scores Protect Revenue
- Malnourishment 'Epidemic' Plagues Hospitals? Really?
- Hospitals and doctors fail patients by passing the buck on insurance rules